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A B S T R A C T 
Obesity is associated with several co-morbidities including chronic pain. Systemic low-grade chronic 
inflammation and dysregulation of pro-inflammatory cytokines have been proposed to underlie these 
phenomena. This study characterized pain and inflammation, and levels of the pro-inflammatory cytokine 
visfatin, in a rodent model of obesity, and investigated whether treatment with the visfatin inhibitor, FK866, 
has anti-inflammatory and/or analgesic effects in normal and obese rats. The effects of pre-administration 
of FK866 (3, 10 mg/kg; i.p.) on carrageenan (3%; i.d. into the left paw)-induced thermal and mechanical 
hypersensitivity and paw oedema was measured in adult male Wistar rats fed a normal diet (ND) or high fat 
diet (HFD) for 12 weeks. HFD-fed rats displayed an increased sensitivity to acute mechanical nociceptive 
stimulation, and potentiated mechanical hyperalgesia and peripheral inflammation to carrageenan. Levels 
of circulating visfatin were increased in HFD-fed rats. Treatment with FK866, a visfatin inhibitor, was 
effective in reducing carrageenan-induced hyperalgesia and paw oedema in both ND-fed and HFD-fed rats. 
These data show that FK866 has anti-inflammatory and analgesic properties. The potentiated response to 
pain and inflammation, and elevated visfatin levels in HFD-fed rats supports the hypothesis that obesity is 
a chronic low-grade inflammatory disorder. Reversal of this co-morbidity by blocking visfatin may be a 
novel therapeutic strategy for managing pain with obesity. 
 




Obesity is an energy-rich condition associated with over-nutrition, which 
impairs systemic metabolic homeostasis and physical mobility [1, 2]. 
Increased body weight in humans is directly linked to development of 
chronic pain conditions including osteoarthritis, lower back pain, 
migraine, hyperuricemia, gouty arthritis and musculoskeletal pain [3-5]. 
Expansion of adipose tissue with obesity is associated with altered 
inflammatory cytokine or ‘adipokine’ secretion, which is now known to 
directly contribute to inflammation and associated pain [6-8]. 
 
Visfatin, also known as a nicotinamide phosphorybosyltransferase 
(NAMPT), the limiting enzyme in nicotinamide adenine dinucleotide 
(NAD) biosynthesis, and identical to previously identified pre-B cell 
colony-enhancing factor (PBEF), is a well characterized 52 kDa 
adipokine with insulin mimetic properties [9, 10]. Visfatin is expressed 
in lymphocytes, hepatocytes, muscle and in white adipose tissue 
macrophages and is up-regulated in cancer, inflammation and obesity 
[11-15]. In brain, visfatin is emerging as a neuroprotective factor for 
ischaemic brain injury [16, 17]. A recent study reported that direct 
intracerebroventricular infusion of recombinant NAMPT reduced infarct 
volume in a mouse stroke model through an anti-inflammatory 
mechanism [18]. In other pathways, visfatin/NAMPT has been shown to 
have a pro-inflammatory function, inducing microglial activation in the 
hypothalamus, promoting inflammatory arthritis, and expression of 
inflammatory cytokines in atherosclerosis [19-21]. In addition, the 
specific non-competitive anti-visfatin inhibitor FK866 has been shown 
to reduce inflammation in several animal models including spinal cord 
injury, acute lung injury, and brain injury, by reducing activation of 
astrocytes and Iba1-positive macrophages/microglia and inhibition of 
pro-inflammatory cytokines [16, 22-24]. This suggests that blocking 
visfatin may be a promising therapeutic target for treatment of pain by 
attenuating the inflammatory cytokine cascade associated with 
inflammatory conditions, including obesity.  
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The aim of this study was to investigate the effects of inhibition of 
visfatin after treatment with FK866, on development of pain and 
inflammation in two models of inflammation; an acute experimentally-
induced pain model (carrageenan) and a chronic low-grade inflammation 
model induced by feeding a high fat diet (HFD) for 3 months (model of 
dietary-induced obesity). The expression of visfatin was also 
characterized in peripheral and central tissues in both models. 
 




Adult male Wistar rats (n = 78; 260 - 440 g) were obtained from the 
Bioscience unit at Glasgow Caledonian University. Animals were 
housed in plastic cages (3 rats per cage) under a 12h light/12h dark 
schedule in a humidity-controlled room. Animals had access to food and 
water ad libitum and monitored daily. All studies were approved by the 
Institute’s Ethics and Welfare Committee and all procedures were in 
accordance with the UK Animals Scientific Procedures Act (1986). 
Animals were treated in accordance with the Ethical Guidelines for 
Investigations of Experimental Pain in Conscious Animals as issued by 
the International Association for the Study of Pain. 
 
II Characterization of a Model of Pre-Diabetic Obesity 
 
Adult male Wistar rats (n = 12; 267 - 390 g) were fed either a normal 
diet (ND; RM1; 2.9% of fat; Special Diet Services, UK; n = 6), or high 
fat diet (HFD; 22%; #821424; Special Diet Services, UK; n = 6) for 12 
weeks. Body weight and blood glucose levels from non-fasting rat tail 
vein was measured weekly from week 0 to week 12 using an electrical 
scale and Accu-Chek Aviva Glucometer, respectively. Thermal and 
mechanical nociceptive responses to hind paw stimulation were recorded 
every second week for the duration of the study. At the end of the study 
(week 12) rats were fasted for 8 hours before being terminally 
anaesthetized by i.p. injection of pentobarbital sodium (5 mg/100 g; 
pharmasol, JM Loveridge PLC, Southampton, UK) and abdominal white 
adipose tissue and spinal cord tissues were collected and stored at -80C. 
Blood (5 ml collected by cardiac puncture) was also collected, and serum 




For the nociception recordings, animals were placed in the recording 
apparatus (thermal and mechanical nociception) for 20 minutes for 5 
consecutive days to acclimatize the rat to the apparatus. Behavioural 
testing for rats was performed between the hours of 0900 and 1200. Pre-
readings (baseline readings) were taken 24 hours prior to start of the 
study (time 0). The Hargreaves test was used to measure thermal 
response latency (in seconds) (Harvard Apparatus, UK). Mechanical 
response thresholds (in grams/Force) were measured using the Ugo 
Basile dynamic plantar aesthesiometer (Harvard Apparatus, UK). Three 
or four readings were taken from each hind paw, and the average of these 
readings taken. Paw volume (cm3) of both hind paws was measured at 0, 
6 and 24 h post-carrageenan using an Ugo Basile plethysmometer 
(Linton Instrumentation, UK). Paw oedema is represented as mean 
percentage difference in volume between ipsilateral (left) and 
contralateral (right) paw.  
IV Metabolic Measurements 
 
Total fasting-plasma triglyceride levels were measured using a 
Triglyceride (Trigs) determination kit (Randox, UK), cholesterol 
measured using a Cholesterol Quantitation Kit (Sigma-Aldrich, UK), 
and insulin levels assayed using an Insulin Rat Insulin ELISA Kit 
(Thermo Scientific, UK), all following the manufacturer’s protocol.  
 
V Characterisation of Visfatin Expression in Serum, White 
Adipose and Spinal Cord Tissue  
 
Levels of visfatin mRNA in spinal cord and white adipose tissue were 
measured using TaqMan semi-quantitative real-time PCR, on the CFX96 
Real-Time PCR detection System (Bio-Rad, UK). Each cDNA sample 
was tested in duplicate and all PCR reactions contained 10 µl Master 
Mix (Primer design, UK), 6.5 µl molecular biology grade water (Fisher 
Scientific, UK), 0.75 µl all of each of forward (10 pmol/l) and reverse 
primer (10 pmol/l) and 1 l of FAM/TAMRA dual labelled probe (5 
pmol/l) (Primer design, UK). For relative quantification of mRNA, the 
comparative ΔΔCt method was used (Applied Biosystems; User Bulletin 
2). The visfatin Enzyme Immunoassay (EIA) Kit (Sigma Aldrich, UK) 
was used to measure visfatin peptide levels in serum, following the 
manufacturer’s protocol.  
 
VI The Effect of FK866 on Carrageenan-Induced Inflammation 
in Normal Rats 
 
Adult male Wistar rats (n = 22; 260 - 313 g) fed a normal diet (ND; RM1; 
2.9% of fat; Special Diet Services, UK) were injected intraperitoneally 
(i.p.) with either vehicle (0.5 ml/kg; control group, n = 8), 3 mg/kg 
FK866 (n = 6) or 10 mg/kg FK866 (n = 8) 15 minutes before carrageenan 
injection (3 mg/ml; i.d.) into the left hind paw. A separate group of rats 
were terminally anaesthetized 6 hours post carrageenan or saline (n = 
6/group; i.d.) and abdominal white adipose tissue and spinal cord tissues 
were processed for expression of visfatin mRNA using Taqman semi-
quantitative real-time PCR, as above. 
 
VII The Effect of FK866 on Carrageenan-Induced 
Inflammation in Obese Rats 
 
Adult male Wistar rats (n = 18; 313 - 440 g) were fed either ND (control 
group; n = 6), or high fat diet (HFD; n = 6/group) for 12 weeks. The 
effects of carrageenan on ND fed rats injected with vehicle (0.5 ml/kg; 
i.p.), and HFD rats injected with either vehicle (0.5 ml/kg; i.p.) or FK866 
(10 mg/kg; i.p.) 15 minutes before carrageenan injection (3 mg/ml; i.d.) 
into the left hind paw. Body weight was measured every four weeks from 
week 0 to week 12 using an electrical scale. Blood glucose levels from 
non-fasting rat tail vein were also measured on week 0 then 12 weeks 




FK866 (Tocris, UK) was dissolved in 2 ml of 10% dimethyl sulfoxide 
solvent (DMSO). Carrageenan (λ-carrageenan type IV; Sigma, UK) was 
dissolved in phosphate-buffered saline (Thermo Fisher Scientific, UK) 
to make a 3% solution 24 h before the start of each study and stored at 
4ºC. Rats received a 50 µl intradermal injection of carrageenan or saline 
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into the plantar surface of the left hind paw and responses to thermal and 
mechanical hind paw stimulation were measured before (time 0) and 2, 
4, 6 and 24 h post-carrageenan. 
 
IX Statistical Analysis 
 
Statistical analyses were performed using GraphPad Prism™ (v6.05; 
UK). Data were analysed using a repeated measures ANOVA test to 
compare control and experimental groups over time. Body weight and 
blood glucose were analysed using a t-test to compare control and obese 
groups. One-way ANOVA test was used to measure carrageenan 
hyperalgesia in control rats over 24 hours. The maximum effect (Emax) 
was also calculated for each animal as the maximum change in response 
or paw volume (after treatment) from baseline. These data were analysed 
using the one-way ANOVA with post-hoc Tukey’s tests. A value of p < 





I Characterization of a Model of Pre-Diabetic Obesity 
 
Metabolic Measurements: Rats fed a HFD gained significantly more 
body weight by 12 weeks (P < 0.01 vs normal diet (ND)-fed rats) but 
remained normoglycaemic (Table 1). Levels of circulating insulin and 
cholesterol at 12 weeks were significantly increased in HFD-fed rats (P 
< 0.01 vs ND-fed rats), while triglycerides remained unchanged (Table 
1). Acute Nociception: Rats fed a HFD showed a significant reduction 
in mechanical withdrawal thresholds at 6 weeks, which persisted until 
the end of study (all P < 0.05 vs. ND-fed rats; Figure 1B). There was no 
change in thermal responses (Figure 1A). Visfatin Expression: Levels of 
circulating visfatin measured by ELISA were significantly increased at 
12 weeks in HFD-fed rats (P < 0.05; Figure 1C). Visaftin mRNA was 
detected in white adipose tissue (Figure 1D) and spinal cord (Figure 1E) 


























Figure 1: Characterisation of a model of pre-diabetic obesity. A) Thermal response latencies (in seconds) and B) mechanical thresholds (in grams) measured 
in the hind paws of normal diet (ND)- and high fat diet (HFD)-fed rats over 12 weeks. C) Visfatin levels in circulation, D) mRNA in white adipose tissue 
and E) spinal cord were measured in ND- and HFD-fed rats at 12 weeks. Expression of mRNA levels is expressed relative to the housekeeping gene 
cyclophilin. All data are mean ± SEM for n = 6 per group: * P < 0.05; **P < 0.01; *** P < 0.001 vs. ND. 
 
Table 1: End point total weight gain (g) and percentage weight gain (%), serum glucose, cholesterol, triglyceride (TAG) (mmol/l), and insulin (ng/ml) levels 
measured in rats fed a normal Diet (ND) or high fat diet (HFD) for 12 weeks (n = 6 per group). Significant difference (t-test): ** P < 0.01; *** P < 0.001 
vs. ND rats. 
Title 1 ND-fed rats HFD-fed rats 
Body weight gain (g) 141 ±17.07 168 ± 22.6 
Body weight gain (%) 39.7 ± 3.2% 54.1 ± 1.6%** 
Glucose (mmol/L) 7.1 ± 0.2 7.5 ± 0.2 
Insulin (ng/ml) 0.14 ± 0.01 1.56 ± 0.16*** 
Cholesterol (mmol/L) 4.2 ± 0.4 6.4 ± 0.3** 
TAG (mmol/L) 0.97 ± 0.16 1.32 ± 0.16 
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II The Effect of FK866 on Carrageenan-Induced Inflammation 
in Normal Rats 
 
Intraplantar injection of carrageenan into the hind paw induced 
significant thermal and mechanical hyperalgesia at 2, 4, 6, and 8 h post-
carrageenan in vehicle treated animals (One-way ANOVA: P < 0.01 vs. 
baseline; Figure 2A); maximum hyperalgesia was observed 6 h post-
carrageenan (P < 0.001 vs. baseline). Repeated measures ANOVA 
showed pre-administration of 10 mg/kg FK866 (but not 3 mg/kg) 
significantly attenuated mechanical hyperalgesia at 6 h (P < 0.01 vs. 
vehicle; Figure 2B). An analysis of Emax revealed a significant 
attenuation of carrageenan-induced thermal and mechanical 
hyperalgesia by FK866 (both P < 0.01 for 10 mg/kg vs. vehicle; Figure 
2C & 2D). Paw oedema was also observed 6 and 24 h post-carrageenan 
in vehicle treated animals (increase of 99 ± 13.2% and 64.5 ± 11.7%, 
respectively; P < 0.02, P < 0.01 vs. contralateral paw, respectively; 
Figure 2E). Pre-administration 10 mg/kg FK866 (but not 3 mg/kg) 
significantly reduced paw oedema to 62.3 ± 7.1% at 6 hours (P < 0.05 











































Figure 2: The effect of intraperitoneal administration of FK866 (3 and 10 mg/kg) or drug vehicle (DMSO), 15 minutes pre-carrageenan on A & C) thermal 
and B & C) mechanical hyperalgesia and D) paw oedema in normal Wistar rats. Mean thermal latency (in seconds; A) and mechanical response threshold 
(in grams; B) in the ipsilateral hind paw at 0, 2-, 4-, 6-, 8- and 24-hours post-carrageenan. Maximum change in thermal and mechanical responses (C) in the 
ipsilateral and contralateral paw post-carrageenan are represented as mean % change (Emax %) from baseline responses. Significant attenuation of 
hyperalgesia by 10 mg/kg FK866: ** P < 0.01 vs. vehicle. E) Paw oedema is represented as mean % change in paw volume from the contralateral paw at 6 
and 24 hours. Significant attenuation of paw oedema by 10 mg/kg FK866: * P < 0.05 vs. vehicle. 
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III The Effect of FK866 on Carrageenan-Induced Inflammation 
in Obese Rats 
 
Rats fed a HFD for 12 weeks remained normoglycaemic but gained 
significantly more weight than ND-fed rats, in line with the previous 
study (both groups P < 0.001; Table 2). Carrageenan induced significant 
thermal and mechanical hyperalgesia in ND-fed rats, as expected, but 
induced a potentiated mechanical hyperalgesia in HFD-fed rats at 4 h (P 
< 0.01 vs. ND-fed rats) and 8 h (P < 0.001 vs. ND fed rats) post-
carrageenan (Figure 3B). An analysis of Emax confirmed augmented 
carrageenan-induced mechanical hyperalgesia (P < 0.001 vs. ND-fed 
rats; Figure 3D). There was no change in thermal hyperalgesia in HFD-
fed rats compared to ND-fed rats (Figures 3A & 3C). Carrageenan 
induced paw oedema was also significantly increased in HFD-fed rats at 
6 and 24 h post-carrageenan (both P < 0.05 vs. ND-fed rats; Figure 3E). 
Treatment with FK866 attenuated potentiated mechanical hyperalgesia 
(P < 0.05 vs. HFD + vehicle; Figure 3D) and paw swelling in HFD-fed 

































Figure 3: The effect of intraperitoneal administration of FK866 (10 mg/kg) or drug vehicle (DMSO) 15 minutes pre-carrageenan on B & C) thermal and 
mechanical hyperalgesia and D) paw oedema in normal diet (ND) and high fat diet (HFD) fed rats. A) Mean thermal latency (in seconds); and mechanical 
response threshold (in grams); B) measured in the ipsilateral hind paw at 0, 2-, 4-, 6-, 8- and 24-hours post-carrageenan. Maximum change in thermal and 
mechanical responses (C) in the ipsilateral and contralateral paw post-carrageenan are represented as mean % change (Emax %) from baseline responses. 
Significant difference between groups: *P < 0.05; ** P < 0.01; ***P < 0.001 vs. vehicle. E) Paw oedema is represented as mean % change in paw volume 
from the contralateral paw at 6 and 24 hours. Significant increase in paw oedema in HFD rats: *P < 0.05 vs. ND + vehicle. Significant attenuation of paw 
oedema by FK866:  P < 0.05 vs. HFD + vehicle. 
 
Table 2: End point total weight gain (g) and serum glucose levels (mmol/l) measured in rats (n = 6 per group) fed a normal diet (ND) for 12 weeks and 
injected with vehicle, and rats fed a high fat diet (HFD) for 12 weeks and injected with vehicle or FK866 (10 mg/kg). Significant difference (one-way 
ANOVA): *** P < 0.001 vs. ND rats. 
 ND + Vehicle HFD + Vehicle HFD + FK866 
Body weight gain (g) 62 ± 6.5 183 ± 19*** 195 ± 15*** 
Body weight gain (%) 17 ± 4.8% 50 ± 15%*** 49± 8.7%*** 
Glucose (mmol/L) 3.9 ± 0.2 4.1 ± 0.2 4.3 ± 0.15 
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IV Expression of Visfatin mRNA in Acute Inflammation 
 
Analysis of levels of visfatin mRNA in spinal cord from ND-fed rats 6 
hours post-carrageenan or saline injection revealed a significant up-
regulation of visfatin mRNA in spinal cord (1.8-fold increase; P < 0.02 
vs. saline-control). There was no change in levels of visfatin mRNA in 















Figure 4: Visfatin mRNA expression in A) white adipose tissue and in B) spinal cord tissues of normal rats (Control; n = 6) injected intraperitoneally with 
vehicle or carrageenan (carrageenan; n = 6). Expression of mRNA levels are expressed relative to the housekeeping gene, cyclophilin. Data are presented 




In this study, feeding rats a high fat diet for 12 weeks induced a pre-
diabetic phenotype, characterised by increased body weight, 
hyperinsulinaemia and hypercholesterolaemia but normoglycaemia and 
normotriglyceridaemia. These rats displayed an increased sensitivity to 
acute mechanical stimulation, and potentiated mechanical hyperalgesia 
and peripheral inflammatory response to carrageenan. Levels of 
circulating visfatin were also increased in these rats, indicative of a pro-
inflammatory state and indicating that this mediator may be linked to 
altered pain processing observed in these rats. Further investigations into 
the functional role of visfatin in this model, revealed that treatment with 
FK866, a visfatin inhibitor, was effective in reducing carrageenan-
induced hyperalgesia in both normal and high-fat diet fed rats. 
 
It is now well established that pain and obesity are closely related, and 
that the incidence of pain conditions is higher in obese individuals [5, 
25]. Obese animals also display increased pain sensitivity to acute 
nociceptive stimuli, although responses are variable with some studies 
reporting no difference in sensitivity to noxious stimulation or reduced 
sensitivity in obese animals [26-29]. In the present study, rats fed a high 
fat diet displayed increased mechanical sensitivity by 6 weeks, before 
significant weight gain, suggesting that changes in diet even in the short-
term may have an impact on nociceptive behaviour. Perhaps more 
striking is the evidence that inflammatory pain and peripheral 
inflammation are potentiated in obese animals. In the current study, rats 
fed a high fat diet displayed enhanced paw swelling and mechanical 
hyperalgesia in response to carrageenan compared to normal diet-fed 
rats, which is similar to the finding reported previously in this laboratory 
utilizing obese Zucker rats [28]. Similarly, feeding rats a high-fat diet 
has been reported to induce visceral hypersensitivity, increased post-
operative pain, and increased paw oedema in diet-induced obese rats 
after intraplantar injection of complete Freund’s adjuvant, a model of 
arthritis [27, 30, 31]. These studies confirm that exposure to high-fat diet 
and resulting obesity induces alterations in both central and peripheral 
pain processing and enhanced inflammatory pain similar to that often 
reported in patients with obesity. 
 
A number of factors, including increased weight bearing, altered body 
mechanics, lifestyle factors, disturbed sleep and depression have been 
linked to co-morbid pain with obesity [5]. Underlying these phenomena 
appears to be a dysregulation in pro-inflammatory mediators and 
associated activation of the immune system. The increased level of 
circulating visfatin observed in high fat-diet fed rats in the current study 
adds to the growing list of inflammatory biomarkers reported to be 
increased with obesity, and similarly seen in a range of painful 
conditions [32-34]. Previous studies have identified visfatin as a marker 
of inflammation; a meta-analysis carried out by Chang et al. showed that 
serum visfatin levels were increased in individuals with obesity, type 2 
diabetes mellitus, metabolic syndrome and cardiovascular diseases [10, 
35, 36]. This study also identified a positive correlation between visfatin 
levels and insulin resistance in line with the current findings in high fat 
diet-fed rats. Visfatin promotes inflammation directly through activation 
of the STAT3/NFκB pathway, and production of pro-inflammatory 
cytokines, and it’s this mechanism that likely contributes to increased 
pain observed in high fat diet-fed rats [37, 38]. Interestingly, serum 
levels of visfatin and nociception were both reduced in an experimental 
peripheral neuropathic pain model in mice after treatment with 
pregabalin [39].  
 
Alterations in inflammatory cytokine production are not restricted to the 
periphery and resulting systemic inflammation. Growing evidence 
supports alterations in central immune signaling in pain with obesity. For 
instance, a recent study reported elevated macrophage levels in lumbar 
dorsal root ganglion in high fat diet-fed rats with enhanced post-
operative pain, while another study reported activation of microglia in 
brain areas related to increased visceral pain in diet-induced obesity [30, 
31]. Indeed, visfatin was reported to activate hypothalamic microglial 
cells, known to be involved in modulation of nociceptive transmission 
under pathological conditions and to release of neurotoxic factors [19, 
40, 41]. In the present study, visfatin mRNA was detected in spinal cord 
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tissue, a key relay station for pain signaling, and although there was no 
change in expression with obesity, we did see an increase in expression 
in spinal cord at 6 hours post-carrageenan, presumably as a consequence 
of the afferent barrage from the inflamed paw. It is interesting to 
speculate on a function role for visfatin in spinal cord tissue, and the 
down-stream effects on cytokine signaling; further studies localizing 
visfatin to specific cell types in this region are warranted.  
 
Visfatin blockers have shown promise as therapeutic agents in a number 
of conditions. FK866 competitively inhibits NAD enzymatic activity by 
binding to the active site formed by the dimer [42]. Functional inhibition 
of visfatin by FK866 in the current study produced anti-inflammatory 
and anti-hyperalgesic effects. FK866 significantly attenuated 
carrageenan-induced thermal and mechanical hyperalgesia and reduced 
paw oedema in both normal and high-fat diet fed rats. This result 
supports a previous finding, which demonstrated that FK866 injection 
after spinal cord injury is effective in reducing secondary inflammatory 
injury and partly reducing permanent damage in the spinal cord [22]. 
Blocking visfatin has been reported to inhibit production of 
inflammatory cytokines by human monocytes and reduce inflammation 
in collagen-induced arthritis [43, 44]. Another recent study reported that 
FK866 blocks the increase of pro-inflammatory cytokines induced by 
LPS by reversing activation of the STAT3/NFκB pathway [45]. These 
results indicate a key role for visfatin in modulating inflammatory pain. 
Furthermore, the reduction in potentiated hyperalgesia and paw swelling 
in high-fat diet fed rats, with elevated circulating visfatin levels, supports 
a role for visfatin in enhanced pain with obesity. Further studies will 
confirm if anti-visfatin therapies can alleviate inflammatory pain and the 
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